Navigation Links
Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Date:2/26/2008

PRINCETON, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the completion of recruitment in the company's multi-center Phase 2a clinical study of PS433540 (DARA), the company's lead internal product candidate. The objective of the Phase 2a randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of 200 and 500 mg of PS433540 in subjects with Stage I and Stage II hypertension.

"We have made good progress advancing DARA's clinical development. Not only did we initiate this Phase 2a study approximately six months ahead of our original clinical development timeline, but we have now completed enrollment in the study with the expectation of reporting results in the second quarter of 2008," said Les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "As this is the first PS433540 study to include hypertensive patients, we are pleased to have the opportunity to demonstrate that DARA can effectively lower blood pressure in this patient population."

Results from Phase 1 studies of PS433540 in normal subjects have indicated that the compound was well tolerated at all doses up to and including 1,000 mg a day for 14 days. Several studies including the multiple ascending dose (MAD) and angiotensin II challenge studies have shown that PS433540 appears to have a pharmacokinetic profile consistent with once-daily oral administration. In the angiotensin challenge study, 250 and 500 mg of PS433540 fully blocked the increase in blood pressure induced by administration of angiotensin II (AII) to healthy volunteers at least as well as 300 mg of irbesartan, the t
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
9. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation ... its CytoSorb® blood purification technology to help fight ... in 28 countries worldwide, today announced the appointment ... MD, FACS, as its Senior Vice President of ... Dr. Di Russo is an ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Ill., Feb. 8, 2011 Sysmex America, Inc. ... Service Agreement with PeaceHealth, a not-for-profit integrated healthcare ... group clinics and laboratories located in Alaska, Washington ... the agreement ensures either the installation of a ...
... MedShape Solutions, Inc., the industry ... announced the introduction and first human clinical use ... fixation device that simplifies and improves soft tissue ... surgery. After receiving 510(k) clearance from the U.S. ...
Cached Medicine Technology:PeaceHealth Standardizes Hematology Operations With Sysmex 2PeaceHealth Standardizes Hematology Operations With Sysmex 3MedShape Solutions, Inc. Announces Breakthrough in ACL Reconstruction 2MedShape Solutions, Inc. Announces Breakthrough in ACL Reconstruction 3
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... News) -- Overeating is common during the holidays, but there ... expert says. "Don,t arrive at a party hungry. It ... you,ll be attending a party, but deprivation leads to hunger, ... Northern Westchester Hospital in Mount Kisco, N.Y., said in a ... the day and even to have a snack before attending ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Each year ... and 2 million hospital admissions across the nation (according ... ). The CDC’s National Hospital Ambulatory Medical Care ... a survey conducted in 2010. They estimated that there ... that resulted in a primary diagnosis of broken bone ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... rapid spread and growing variety of unregulated tobacco products, ... and broader regulation // to prevent more than five ... ,The agency also called for anti-tobacco programmes, especially aimed ... was apparently increasing. ,Tobacco use, it finds, also ...
... to computerize NHS with ?20 billion is becoming late than scheduled by about two ... records electronically for 50 million NHS patients, but this will not still be started ... programme for IT (NPfIT) really costs more than three times than the previously said ... ...
... P J Abdul Kalam today met representatives of the ... impasse with the students and doctors deciding// to continue ... medicos, which also included members of AIIMS Faculty Association ... 45-minute meeting with Kalam. The medicos presented a charter ...
... research that showed that high fat in the diet ... a high fat intake is even beneficial// and protective ... Granger and colleagues from the Menzies Research Institute in ... in Melbourne studied 652 people who had been diagnosed ...
... strokes in young people, though the condition's progress can be ... ,The disorder known as Fabry disease is characterised by attacks ... skin lesions and progressive renal insufficiency. ,It is ... body to process oils, waxes and fatty acids, reports the ...
... makes the condition worse and it is in a position ... profession// to makeup the shortfall. Most strugglers were the remote ... rise in female part-time GPs, more workloads and immence retirement ... such hardest shortage’. ,Dr Brian McKinstry, a ...
Cached Medicine News:Health News:President Kalam Meets Striking Medicos However Stir to Continue 2Health News:Rare Genetic Disorder Could Cause Strokes In Young People 2Health News:Scotland Faces Shortage Of GPs 2
... The IQmarkTM Diagnostic Workstation Software ... Software System that digitally stores many ... Designed with Microsofts open-architecture products in ... as EMR integration (using ActiveX controls), ...
... The IQmark Digital ECG is a highly ... conventional Microsoft Windows personal computer. Everything you need ... included. The acquisition and operating costs of the ... of oldstyle, stand-alone ECG machines (even including the ...
... Trichloroacetic acid (TCA) peels are often thought ... discomfort. PCA Professional™ TCA peels are very ... are blends formulated with many ingredients including ... phytohormones and kojic and azelaic acids to ...
It works by stimulating new growth of skin and collagen by decreasing the bond that holds dead skin cells on the surface. This allows dead cells to be removed gradually, leaving behind a layer of smo...
Medicine Products: